| Literature DB >> 36210440 |
Farnia Velayati1,2, Haleh Ayatollahi3, Morteza Hemmat4, Reza Dehghan5.
Abstract
BACKGROUND: Telehealth services can utilize various information technologies and improve quality and efficiency of healthcare delivery by facilitating education, treatment, follow-up, and decision-making. However, these services are not always commercialized, and in case of commercialization, there is no guarantee for their long-term sustainability in market. Therefore, business models and frameworks are used as part of commercialization processes to identify a set of factors affecting the sustainability, effectiveness, and key business activities. The current study aimed to develop a telehealth business framework for Iran.Entities:
Keywords: Business; Health service marketing; Telehealth; Telemedicine
Mesh:
Year: 2022 PMID: 36210440 PMCID: PMC9548305 DOI: 10.1186/s12911-022-02011-4
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 3.298
Participants’ characteristics in the first, second and third rounds of the Delphi study
| Variables | Round one | Round two | Round three |
|---|---|---|---|
| Frequency (%) | Frequency (%) | Frequency (%) | |
| Sex | |||
| Male | 12 (57.1) | 10 (71.4) | 10 (71.4) |
| Female | 9 (2.9) | 4 (28.6) | 4 (28.6) |
| Age (years) | |||
| 30–40 | 6 (28.6) | 4 (28.6) | 4 (28.6) |
| 41–50 | 7 (33.3) | 3 (21.4) | 3 (21.4) |
| 51–60 | 7 (33.3) | 7 (50) | 7 (50) |
| 61–70 | 1 (4.8) | 0 | 0 |
| Education | |||
| Ph.D. | 18 (85.7) | 12 (85.7) | 12 (85.7) |
| M.Sc. | 3 (14.3) | 2 (14.3) | 2 (14.3) |
| Job | |||
| Faculty member | 17 (81) | 12 (85.7) | 12 (85.7) |
| Start-up manager | 4 (19) | 2 (14.3) | 2 (14.3) |
| Work experience (years) | |||
| ≤ 15 | 8 (38) | 5 (35.7) | 5 (35.7) |
| 15 < | 13 (62) | 9 (64.3) | 9 (64.3) |
Participant’s responses about the importance of the components in telehealth business prerequisites and production dimensions (Round one)
| No | Dimensions | Components | Subcomponents | Very important | Important | Neutral | Less important | Unimportant | Mean ± SD | Median (1st–3rd quartile) | Agreement |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | |||||||
| 1 | Telehealth business prerequisites | Value proposition | Financial value | 11 (52.4) | 5 (23.8) | 5 (23.8) | 0 | 0 | 4.28 ± 0.84 | 5 (4–5) | |
| 2 | Non-financial value | 13 (61.9) | 6 (28.6) | 1 (4.8) | 1 (4.8) | 0 | 4.47 ± 0.81 | 5 (4–5) | ✓ | ||
| 3 | Value capture | 11 (52.4) | 6 (28.6) | 4 (19) | 0 | 0 | 4.33 ± 0.79 | 5 (4–5) | ✓ | ||
| 4 | Delivering value | 7 (33.3) | 11 (52.4) | 2 (9.5) | 1 (4.8) | 0 | 4.14 ± 0.79 | 4 (4–5) | ✓ | ||
| 5 | Business initial requirements | Intellectual property rights | 11 (52.4) | 7 (33.3) | 3 (14.3) | 0 | 0 | 4.38 ± 0.74 | 5 (4–5) | ✓ | |
| 6 | Trust in idea registration centers | 8 (38.1) | 7 (33.3) | 5 (23.8) | 1 (4.8) | 0 | 4.04 ± 0.92 | 4 (3–5) | * | ||
| 7 | Time lag between the idea generation and manufacturing | 11 (52.4) | 4 (19) | 4 (19) | 2 (9.5) | 0 | 4.14 ± 1/06 | 5 (3–5) | * | ||
| 8 | Team working skills | 16 (76.2) | 5 (23.8) | 0 | 0 | 0 | 4.67 ± 0.43 | 5 (5–5) | ✓ | ||
| 9 | Business plan | 11 (52.4) | 9 (42.9) | 1 (4.8) | 0 | 0 | 4.47 ± 0.60 | 5 (4–5) | ✓ | ||
| 10 | Partners’ expertise | 12 (57.1) | 9 (42.9) | 0 | 0 | 0 | 4.57 ± 0.50 | 5 (4–5) | ✓ | ||
| 11 | Required capital and financial resources | 12 (57.1) | 9 (42.9) | 0 | 0 | 0 | 4.75 ± 0.50 | 5 (4–5) | ✓ | ||
| 12 | Telehealth business production | Key resources | Human resources | 18 (85.7) | 3 (14.3) | 0 | 0 | 0 | 4.85 ± 0.35 | 5 (5–5) | ✓ |
| 13 | Physical resources | 6 (28.6) | 11 (52.4) | 4 (19) | 0 | 0 | 4.09 ± 0.70 | 4 (4–5) | ✓ | ||
| 14 | Financial resources | 11 (52.4) | 7 (33.3) | 3 (14.3) | 0 | 0 | 4.38 ± 0.74 | 5 (4–5) | ✓ | ||
| 15 | Key activities | Multi-stage assessment of the product | 11 (52.4) | 9 (42.9) | 1 (4.8) | 0 | 0 | 4.47 ± 0.60 | 5 (4–5) | ✓ | |
| 16 | Research and analysis | 16 (76.2) | 4 (19) | 1 (4.8) | 0 | 0 | 4.71 ± 0.56 | 5 (5–5) | ✓ | ||
| 17 | Marketing and branding | 12 (57.1) | 9 (42.9) | 0 | 0 | 0 | 4.57 ± 0.50 | 5 (4–5) | ✓ | ||
| 18 | Business counselling and mentorship | 8 (38.1) | 12 (57.1) | 1 (4.8) | 0 | 0 | 4.33 ± 0.57 | 4 (4–5) | ✓ | ||
| 19 | Effective communication with the stakeholders | 8 (38.1) | 11 (52.4) | 2 (9.5) | 0 | 0 | 4.28 ± 0.64 | 4 (4–5) | ✓ | ||
| 20 | Risk management (e.g., clinical, legal, and market risks) | 11 (52.4) | 8 (38.1) | 2 (9.5) | 0 | 0 | 4.42 ± 0.67 | 5 (4–5) | ✓ | ||
| 21 | Telehealth business production | Key partners | Legal partners (Public and private companies) | 5 (23.8) | 14 (66.7) | 1 (4.8) | 1 (4.8) | 0 | 4.09 ± 0.70 | 4 (4–4) | ✓ |
| 22 | Real partners (e.g., physician, patients, treatment staff) | 12 (57.1) | 8 (38.1) | 1 (4.8) | 0 | 0 | 4.52 ± 0.60 | 5 (4–5) | ✓ | ||
| 23 | NGOs’ partnership | 4 (19) | 6 (28.6) | 10 (47.6) | 0 | 1 (4.8) | 3.57 ± 0.97 | 3 (3–4) | * | ||
| 24 | Licenses and permissions | Security-based licenses | 14 (66.7) | 5 (23.8) | 2 (9.5) | 0 | 0 | 4.57 ± 0.67 | 5 (4–5) | ✓ | |
| 25 | General and optional licenses | 3 (14.3) | 12 (57.1) | 3 (14.3) | 1 (4.8) | 2 (9/5) | 3.61 ± 1.11 | 4 (3–4) | * | ||
| 26 | Legislations in all areas | 13 (61.9) | 4 (19) | 2 (9.5) | 1 (4.8) | 1 (4.8) | 4.28 ± 1.14 | 5 (4–5) | ✓ | ||
| 27 | Stakeholders | Partnership with stakeholders | 12 (57.1) | 8 (38.1) | 1 (4.8) | 0 | 0 | 4.52 ± 0.60 | 5 (4–5) | ✓ | |
| 28 | Discussions between the stakeholders | 7 (33.3) | 10 (47.6) | 3 (14.3) | 0 | 0 | 4.04 ± 0.97 | 4 (4–5) | ✓ | ||
| 29 | Stakeholder credibility | 9 (42.9) | 10 (47.6) | 2 (9.5) | 0 | 0 | 4.33 ± 0.65 | 4 (4–5) | ✓ | ||
| 30 | Market | Current and future competitors | 11 (52.4) | 7 (33.3) | 3 (14.3) | 0 | 0 | 4.38 ± 0.74 | 5 (4–5) | ✓ | |
| 31 | Structure of the market | 8 (38.1) | 8 (38.1) | 5 (23.8) | 0 | 0 | 4.14 ± 0.79 | 4 (4–5) | ✓ | ||
| 32 | Marketing and supporting strategies | 12 (57.1) | 8 (38.1) | 1 (4.8) | 0 | 0 | 4.52 ± 0.60 | 5 (4–5) | ✓ | ||
| 33 | Competitiveness in the market | 15 (71.4) | 6 (28.6) | 0 | 0 | 0 | 4.71 ± 0.46 | 5 (4–5) | ✓ | ||
| 34 | Support services | Financial support | 10 (47.6) | 8 (38.1) | 3 (14.3) | 0 | 0 | 4.33 ± 0.73 | 4 (4–5) | ✓ | |
| 35 | Legal and policy protections | 10 (47.6) | 8 (38.1) | 2 (9.5) | 1 (4.8) | 0 | 4.23 ± 0.99 | 4 (4–5) | ✓ | ||
| 36 | Customer and user support | 16 (76.2) | 5 (23.8) | 0 | 0 | 0 | 4.76 ± 0.43 | 5 (5–5) | ✓ | ||
| 37 | Insurance companies’ support | 13 (61.9) | 5 (23.8) | 2 (9.5) | 1 (4.8) | 0 | 4.42 ± 0.87 | 5 (4–5) | ✓ | ||
| 38 | Supporting manufacturers | 10 (47.6) | 8 (38.1) | 2 (9.5) | 0 | 0 | 4.23 ± 0.99 | 4 (4–5) | ✓ | ||
| 39 | Technical services (appropriate technical infrastructure, data exchange standards, confidentiality protocols, etc.) | 16 (76.2) | 5 (23.8) | 0 | 0 | 0 | 4.76 ± 0.43 | 5 (5–5) | ✓ | ||
| 40 | Telehealth business production | Customers and users | Demand-based production | 11 (52.4) | 10 (47.6) | 0 | 0 | 0 | 4.52 ± 0.51 | 5 (4–5) | ✓ |
| 41 | User interface design | 12 (57.1) | 8 (38.1) | 1 (4.8) | 0 | 0 | 4.52 ± 0.60 | 5 (4–5) | ✓ | ||
| 42 | Customer relationship management | 13 (61.9) | 8 (38.1) | 0 | 0 | 0 | 4.61 ± 0.49 | 5 (4–5) | ✓ | ||
| 43 | User training | 10 (47.6) | 11 (52.4) | 0 | 0 | 0 | 4.47 ± 0.51 | 5 (4–5) | ✓ | ||
| 44 | Healthcare delivery models | 11 (52.4) | 9 (42.8) | 1 (4.8) | 0 | 0 | 4.47 ± 0.60 | 5 (4–5) | ✓ | ||
| 45 | User acceptance | 11 (52.4) | 9 (42.8) | 1 (4.8) | 0 | 0 | 4.47 ± 0.60 | 5 (4–5) | ✓ | ||
| 46 | Telehealth business payments and costs | Cost structure | Production and logistics costs | 6 (28.6) | 12 (57.1) | 3 (14.3) | 0 | 0 | 4.14 ± 0.65 | 4 (5–4) | ✓ |
| 47 | Cost of hardware and software infrastructure | 10 (47.6) | 9 (42.8) | 1 (4.8) | 1 (4.8) | 0 | 4.33 ± 0.79 | 4 (5–4) | ✓ | ||
| 48 | Cost of commercialization | 11 (52.4) | 7 (33.3) | 3 (14.3) | 0 | 0 | 4.38 ± 0.74 | 5 (5–4) | ✓ | ||
| 49 | Tax | 6 (28.6) | 4 (19) | 8 (38.1) | 3 (14.3) | 0 | 3.61 ± 1.07 | 3 (3–5) | * | ||
| 50 | Other tangible and intangible costs | 6 (28.6) | 5 (23.8) | 10 (47.6) | 0 | 0 | 3.80 ± 0.87 | 4 (5–3) | * | ||
| 51 | Pricing | Pricing by product manufacturers | 5 (23.8) | 8 (38.1) | 8 (38.1) | 0 | 0 | 3.85 ± 0.79 | 4 (3–4) | * | |
| 52 | Pricing by an independent organization | 4 (19) | 7 (33.3) | 7 (33.3) | 3 (14.3) | 0 | 3.57 ± 0.97 | 4 (3–4) | * | ||
| 53 | Economical pricing | 11 (52.4) | 7 (33.3) | 2 (9.5) | 1 (4.8) | 0 | 4.33 ± 0.65 | 4 (4–5) | ✓ | ||
| 54 | Revenue making | Selling products | 8 (38.1) | 8 (38.1) | 4 (19) | 0 | 1 (4.8) | 4.04 ± 1.02 | 4 (5–4) | ✓ | |
| 55 | Selling data | 4 (19) | 7 (33.3) | 7 (33.3) | 2 (9.5) | 1 (4.8) | 3.52 ± 1.07 | 4 (3–4) | * | ||
| 56 | Receiving payments from product users | 7 (33.3) | 11 (52.4) | 3 (14.3) | 0 | 0 | 4.19 ± 0.67 | 4 (5–4) | ✓ | ||
| 57 | Revenue model | Revenue making strategies | 10 (47.6) | 9 (42.8) | 1 (4.8) | 0 | 1 (4.8) | 4.28 ± 0.95 | 4 (4–4) | ✓ | |
| 58 | Current and future revenue streams | 6 (28.6) | 11 (52.4) | 3 (14.3) | 0 | 1 (4.8) | 4 ± 0.94 | 4 (5–4) | ✓ | ||
| 59 | Financial stability | 14 (66.6) | 6 (28.6) | 1 (4.8) | 0 | 0 | 4.61 ± 0.58 | 5 (5–4) | ✓ | ||
| 60 | Profitability | 11 (52.4) | 7 (33.3) | 1 (4.8) | 1 (4.8) | 1 (4.8) | 4.23 ± 1.09 | 5 (5–4) | ✓ | ||
| 61 | Telehealth business post-production services | Product evaluation | In-person feedback | 7 (33.3) | 8 (38.1) | 4 (19) | 1 (4.8) | 1 (4.8) | 3.90 ± 1.09 | 4 (5–3) | * |
| 62 | Electronic feedback | 7 (33.3) | 11 (52.4) | 3 (14.3) | 0 | 0 | 3.61 ± 1.11 | 4 (3–4) | ✓ | ||
| 63 | Research-based feedback | 8 (38.1) | 9 (42.8) | 4 (19) | 0 | 0 | 4.19 ± 0.74 | 4 (5–4) | ✓ | ||
| 64 | Responsibility of telehealth services | Full responsibility for providing telehealth services | 12 (57.1) | 8 (38.1) | 0 | 0 | 1 (4.8) | 4.47 ± 0.74 | 5 (5–4) | ✓ | |
| 65 | Relative responsibility for providing telehealth services | 3 (14.3) | 10 (47.6) | 7 (33.3) | 1 (4.8) | 0 | 4.04 ± 0.97 | 4 (4–5) | * | ||
| 66 | Product Protection | Patent registration | 5 (23.8) | 8 (38.1) | 4 (19) | 4 (19) | 0 | 3.57 ± 1.24 | 4 (3–4) | * | |
| 67 | Maintaining confidentiality in telehealth services | 12 (57.1) | 5 (23.8) | 3 (14.3) | 1 (4.8) | 0 | 4.33 ± 0.91 | 5 (5–4) | ✓ | ||
| 68 | Official product registration | 10 (47.6) | 9 (42.8) | 2 (9.5) | 0 | 0 | 4.33 ± 0.66 | 4 (5–4) | ✓ | ||
| 69 | Receiving certificate of excellence | 8 (38.1) | 7 (33.3) | 2 (9.5) | 2 (9.5) | 2 (9.5) | 3.80 ± 1.32 | 4 (5–3) | * | ||
| 70 | Product marketing | Traditional marketing | 14 (66.7) | 4 (19) | 3 (14.3) | 0 | 0 | 4.52 ± 0.74 | 4 (5–4) | ✓ | |
| 71 | Digital marketing | 9 (42.8) | 9 (42.8) | 3 (14.3) | 0 | 0 | 4.28 ± 0.71 | 4 (5–4) | ✓ | ||
| 72 | Marketing at scientific congresses and science and technology exhibitions | 9 (42.8) | 5 (23.8) | 4 (19) | 2 (9.5) | 1 (4.8) | 3.90 ± 1.22 | 4 (5–3) | * | ||
| 73 | Making contracts | Commercial contracts | 11 (52.4) | 9 (42.8) | 1 (4.8) | 0 | 0 | 4.47 ± 0.60 | 5 (5–4) | ✓ | |
| 74 | Non-commercial contracts | 4 (19) | 9 (42.8) | 5 (23.8) | 2 (9.5) | 1 (4.8) | 3.61 ± 1.07 | 4 (3–4) | * |
Agreement ✓ No agreement *
Participant’s responses about the importance of the components of a telehealth business framework (Round two of the Delphi study)
| No | Dimensions | Components | Subcomponents | Very important | Important | Neutral | Less important | Unimportant | Mean ± SD | Median (1st–3rd quartile) | Agreement |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | |||||||
| 1 | Telehealth business prerequisites | Business initial requirements | Trust in idea registration centers | 4 (28.6) | 5 (35.7) | 4 (28.6) | 1 (7.1) | 0 | 3.85 ± 0.94 | 4 (3–4.75) | * |
| 2 | Time lag between the idea generation and manufacturing | 11 (78.6) | 3 (21.4) | 0 | 0 | 0 | 4.78 ± 0.42 | 5 (5–5) | ✓ | ||
| 3 | Telehealth business production | Licenses and permissions | General and optional licenses | 6 (42.9) | 8 (57.1) | 0 | 0 | 0 | 4.42 ± 0.51 | 4 (4–5) | ✓ |
| 4 | Telehealth business payments and costs | Cost structure | Other tangible and intangible costs | 9 (64.3) | 2 (14.3) | 3 (21.4) | 0 | 0 | 4.42 ± 0.85 | 5 (4–5) | ✓ |
| 5 | Pricing | Pricing by product manufacturer | 4 (28.6) | 8 (57.1) | 2 (14.3) | 0 | 0 | 4.14 ± 0.66 | 4 (4–4.75) | ✓ | |
| 6 | Pricing by an independent organization | 3 (21.4) | 6 (42.9) | 4 (28.6) | 1 (7.1) | 0 | 3.78 ± 0.89 | 4 (3–4) | * | ||
| 7 | Revenue making | Selling data | 4 (28.6) | 8 (57.1) | 1 (7.1) | 1 (7.1) | 0 | 4.07 ± 0.82 | 4 (4–4.75) | ✓ | |
| 8 | Telehealth business post-production services | Product evaluation | In-person feedback | 7 (50) | 3 (21.4) | 3 (21.4) | 0 | 1 (7.1) | 4.07 ± 1.20 | 4.5 (3.5–4.5) | * |
| 9 | Responsibility of telehealth services | Relative responsibility for providing telehealth services | 5 (35.7) | 7 (50) | 2 (14.3) | 0 | 0 | 4.21 ± 0.69 | 4 (4–5) | ✓ | |
| 10 | Product Protection | Patent registration | 3 (21.4) | 6 (42.9) | 4 (28.6) | 1 (7.1) | 0 | 3.78 ± 0.89 | 4 (3–4) | * | |
| 11 | Receiving certificate of excellence | 6 (42.9) | 5 (35.7) | 2 (14.3) | 1 (7.1) | 0 | 4.14 ± 0.94 | 4 (4–5) | ✓ | ||
| 12 | Product marketing | Marketing at scientific congresses and science and technology exhibitions | 7 (50) | 3 (21.4) | 3 (21.4) | 1 (7.1) | 0 | 4.14 ± 1.02 | 4.5 (3.5–4.5) | ✓ | |
| 13 | Making contracts | Non-commercial contracts | 1 (7.1) | 8 (57.1) | 4 (28.6) | 1 (7.1) | 0 | 3.64 ± 0.74 | 4 (3–4) | * |
Agreement ✓ No agreement *
Participant’s responses about the importance of the components of a telehealth business framework (Round three of the Delphi study)
| No | Dimensions | Components | Subcomponents | Very important | Important | Neutral | Less Important | Unimportant | Mean ± SD | Median (1st–3rd quartile) | Agreement |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | |||||||
| 1 | Telehealth business prerequisites | Business initial requirements | Trust in idea registration centers | 2 (14.3) | 8 (57.1) | 3 (21.4) | 1 (7.1) | 0 | 3.74 ± 0.80 | 4 (3.25–4) | * |
| 2 | Telehealth business payments and costs | Pricing | Pricing by an independent organization | 4 (28.6) | 5 (35.7) | 3 (21.4) | 2 (14.3) | 0 | 3.78 ± 1.05 | 4 (3–4.75) | * |
| 3 | Telehealth business post-production services | Product evaluation | In-person feedback | 6 (42.9) | 5 (35.7) | 2 (14.3) | 0 | 1 (7.1) | 4.07 ± 1.14 | 4 (4–5) | ✓ |
| 4 | Product Protection | Patent registration | 2 (14.3) | 8 (57.1) | 3 (21.4) | 0 | 1 (7.1) | 3.71 ± 0.99 | 4 (3.25–4) | * | |
| 5 | Making contracts | Non-commercial contracts | 0 | 10 (71.4) | 4 (28.6) | 0 | 0 | 3.71 ± 0.46 | 4 (3.25–4) | * |
Agreement ✓ No agreement *
Fig. 1The 4P telehealth business framework for Iran